Avoiding therapeutic pitfalls

The rational use of specifically targeted agents against hepatitis C infection

Barbara H. McGovern, B. K A Dayyeh, Raymond T. Chung

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The development of specifically targeted antiviral agents against hepatitis C is a major therapeutic advance that promises to markedly improve treatment response rates in patients with chronic infection. However, rapid emergence of drug resistance has already been described, the consequences of which are not yet understood. Although there are important differences between hepatitis C (HCV) and human immunodeficiency virus (HIV) infection, the judicious use of candidate agents against HCV should be guided by principles that have been established in the HIV therapeutic arena. In this review, we attempt to draw useful parallels between the development of antiretroviral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection. Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigm, particularly with respect to drug resistance.

Original languageEnglish (US)
Pages (from-to)1700-1712
Number of pages13
JournalHepatology
Volume48
Issue number5
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Hepatitis C
Infection
HIV
Virus Diseases
Drug Resistance
Antiviral Agents
Therapeutics
Hepacivirus

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology

Cite this

Avoiding therapeutic pitfalls : The rational use of specifically targeted agents against hepatitis C infection. / McGovern, Barbara H.; Dayyeh, B. K A; Chung, Raymond T.

In: Hepatology, Vol. 48, No. 5, 11.2008, p. 1700-1712.

Research output: Contribution to journalArticle

McGovern, Barbara H. ; Dayyeh, B. K A ; Chung, Raymond T. / Avoiding therapeutic pitfalls : The rational use of specifically targeted agents against hepatitis C infection. In: Hepatology. 2008 ; Vol. 48, No. 5. pp. 1700-1712.
@article{00b2242c45bc45f08237f6678e5bf85a,
title = "Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection",
abstract = "The development of specifically targeted antiviral agents against hepatitis C is a major therapeutic advance that promises to markedly improve treatment response rates in patients with chronic infection. However, rapid emergence of drug resistance has already been described, the consequences of which are not yet understood. Although there are important differences between hepatitis C (HCV) and human immunodeficiency virus (HIV) infection, the judicious use of candidate agents against HCV should be guided by principles that have been established in the HIV therapeutic arena. In this review, we attempt to draw useful parallels between the development of antiretroviral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection. Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigm, particularly with respect to drug resistance.",
author = "McGovern, {Barbara H.} and Dayyeh, {B. K A} and Chung, {Raymond T.}",
year = "2008",
month = "11",
doi = "10.1002/hep.22563",
language = "English (US)",
volume = "48",
pages = "1700--1712",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Avoiding therapeutic pitfalls

T2 - The rational use of specifically targeted agents against hepatitis C infection

AU - McGovern, Barbara H.

AU - Dayyeh, B. K A

AU - Chung, Raymond T.

PY - 2008/11

Y1 - 2008/11

N2 - The development of specifically targeted antiviral agents against hepatitis C is a major therapeutic advance that promises to markedly improve treatment response rates in patients with chronic infection. However, rapid emergence of drug resistance has already been described, the consequences of which are not yet understood. Although there are important differences between hepatitis C (HCV) and human immunodeficiency virus (HIV) infection, the judicious use of candidate agents against HCV should be guided by principles that have been established in the HIV therapeutic arena. In this review, we attempt to draw useful parallels between the development of antiretroviral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection. Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigm, particularly with respect to drug resistance.

AB - The development of specifically targeted antiviral agents against hepatitis C is a major therapeutic advance that promises to markedly improve treatment response rates in patients with chronic infection. However, rapid emergence of drug resistance has already been described, the consequences of which are not yet understood. Although there are important differences between hepatitis C (HCV) and human immunodeficiency virus (HIV) infection, the judicious use of candidate agents against HCV should be guided by principles that have been established in the HIV therapeutic arena. In this review, we attempt to draw useful parallels between the development of antiretroviral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection. Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigm, particularly with respect to drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=56149086621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149086621&partnerID=8YFLogxK

U2 - 10.1002/hep.22563

DO - 10.1002/hep.22563

M3 - Article

VL - 48

SP - 1700

EP - 1712

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -